Aggressive Periodontitis

Accessible Care for Seniors Signing Up for Medicare Benefits DALLAS, Nov. 20, 2023 /PRNewswire/ -- Open enrollment for Medicare began on October 15. Millions of seniors in Texas once again faced the challenge of finding the right Medicare coverage, including the need to decide between Original Medicare or Medicare Advantage plans. While the primary focus is on medical and prescription coverage, it is important not to ignore the potential impact of dental coverage. Most Medicare participants don't realize the program does not include routine, preventive dental procedures, which are critical to longevity and overall health. Currently, Medicare benefits only apply to surgical dental procedures carried out in hospitals. As a result, seniors must either pay for dental services completely out-of-pocket or try to find a Medicare supplement that provides high-quality, affordable and accessible dental care. Unfortunately, this is extremely difficult. Most Medicare dental supplements are low-cost and poorly designed. In addition, these plans have very limited networks of inexperienced dentists. "We see the challenges seniors face in this situation, which is one reason why we offer our dental membership plans," commented Dr. Jay Patel, who practices at Midtown Family Dentistry of Dallas. He continued, "We simplify the search for experienced and knowledgeable dentists and provide the care seniors need at a reasonable rate. Our adult plan allows everyone to enjoy friendly, personalized care at a consistent, low monthly fee." Furthermore, the negative impact of poor dental care on the overall health of seniors can be significant. A range of statistics tell the story: Only 29% of seniors have dental coverage. 1 in 5 adults aged 65 or older have no natural teeth remaining, and complete tooth loss becomes twice as prevalent by age 75. People who still have 20 or more teeth at age 70 are significantly more likely to have a longer lifespan than those with fewer teeth. 70% of adults over the age of 65 have advanced periodontitis. This is the leading cause of adult tooth loss. In Texas, nearly 4 million senior citizens struggle with periodontal disease – a disease that has been strongly linked to heart disease, Alzheimer's, diabetes, and other serious conditions. While dental membership plans have existed for more than 20 years, most patients are unaware of this option. At the same time, ease of use and enrollment are two of the most significant benefits. Other facts to know about the savings plan at Midtown Family Dentistry of Dallas include: Between 2 dental examinations and cleanings per year included at a fixed cost per month. Benefits are available upon enrollment without any waiting period. Fluoride varnish and X-rays for the year. 20 percent discounts on other treatment, excluding Invisalign and braces. As seniors consider these benefits, it is important to keep a couple of dates in mind. Open enrollment for Medicare started on October 15, 2023, and ends December 7, 2023. This is the time to drop an existing dental supplement that is not working and to enroll in a better form of coverage. Those interested in learning more should feel free to contact Midtown Family Dentistry of Dallas on their website or by calling the office at (469) 780-7844. Contact Information: Website for Midtown Family Dentistry of Dallas: Dr. Jay Patel Dr. Scott Ludlow Dr. Tuan Nguyen 13309 Monfort Dr. Dallas, TX 75240 Amanda Campbell, Client Relations TNT Dental 2100 North Collins Boulevard Richardson, TX 75080 Primary Media Contact: Amanda Campbell [email protected] 877-868-4932 SOURCE Midtown Dallas Dentistry

Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly reduced sleep-related and dopaminergic side effects Data analysis also confirmed patients treated with P2B001 developed significantly less new-onset excessive daytime sleepiness when compared to marketed pramipexole Pharma Two B, a private, venture-backed, late-stage pharmaceutical company, today announced that additional results from the Phase 3 pivotal clinical trial evaluating P2B001, will be presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27 in Boston, MA. The data are being presented as an oral (Abstract 3733) and poster (Abstract 2396) presentation. The data in both presentations are consistent with the positive Phase 3 topline efficacy and safety results presented previously, reemphasizing the potential of P2B001, if approved, to offer a new treatment approach for people with early Parkinson’s disease (PD). Pharma Two B plans to submit a New Drug Application (NDA) for P2B001 to the U.S. Food and Drug Administration (FDA) in 2023. The Phase 3 trial was a global, multi-center, double-blind, parallel group design that enrolled 544 treatment naïve patients with PD (Hoehn-Yahr <3). The primary endpoint was the change from baseline to week 12 in total Unified Parkinson’s Disease Rating Scale (UPDRS) for P2B001 versus its individual components. The key secondary endpoint compared the change from baseline in Epworth Sleepiness Scale (ESS) for P2B001 versus commercial pramipexole-ER (Prami-ER). Excessive daytime sleepiness (EDS) is a commonly reported side effect among people with PD, which often worsens with dopamine agonist (DA) treatmenti. “The results of this Phase 3 trial represent positive news for newly diagnosed PD patients, as there has been a clear unmet need for an initial, once-daily treatment that has demonstrable efficacy and safety, requires no titration and has a lower incidence of excessive daytime sedation compared to pramipexole monotherapy,” says Lawrence W. Elmer, M.D. Ph.D., Department of Neurology, University of Toledo College of Medicine and Life Sciences, and trial investigator. “As a clinician caring for PD patients, I know the side effects from dopamine agonists (DAs) as monotherapy for early PD may be challenging and often limit treatment options, especially for younger people who may be required to drive for their employment and also for older people who often cannot tolerate DA side effects, including excessive daytime somnolence.” The results presented in abstract 3733 demonstrate comparable changes from baseline to week 12 with P2B001 and commercial Prami-ER in total UPDRS scores (-7.98 ±0.6 vs -8.35 ±0.86, p=0.7197) and non-inferiority (post-hoc) of P2B001 was confirmed (margin of 3 points, p=0.0052). Similarly, no significant differences between P2B001 and Prami-ER were seen in total UPDRS responders (≥4-point improvement), UPDRS Part II (activities of daily living/ADL) and UPDRS Part III (motor) scores. Importantly, patients receiving P2B001 versus Prami-ER reported less dopaminergic-related side effects (44.7% vs. 66.2%) and specifically less somnolence (14.7% vs. 31.1%,) and orthostatic hypotension (2.7% vs. 12.2%,) side effects. Trial participants treated with P2B001 had better outcomes in daytime sleepiness, with significantly less worsening (shown by a lower ESS change from baseline) than that with Prami-ER (key secondary endpoint; p < 0.0001). Results highlighted in abstract 2396 show that patients treated with P2B001 developed significantly less new-onset EDS, often a limiting factor for traditional dosing of DAs. Data analysis showed the rate of new-onset EDS was significantly lower in patients treated with P2B001 (8.5%) as compared to commercial Prami-ER (35.7%; adjusted odds ratio 0.17 (95% CI: 0.08-0.36; P<0.0001). “We believe the data presented at AAN this year continue to support the development of P2B001 as a potential first-line therapy for people with PD,” says Dan Teleman, President, Pharma Two B. “Our unique and proprietary formulation shown through our dose selection, extended-release formulation, and no need for titration supports our plan to submit a New Drug Application to the U.S. Food and Drug Administration.” About P2B001 P2B001 is an investigational, novel, fixed-dose, extended-release combination of pramipexole and rasagiline (0.6 mg/0.75 mg), both at low doses that are not commercially available. Marketed pramipexole and rasagiline are currently indicated for the treatment of Parkinson’s disease (as monotherapy and adjunct therapy for early and more advanced patients). P2B001 is being developed for potential use as a first-line therapy for people with Parkinson’s disease of all ages. Extended-release rasagiline is a new and proprietary formulation of rasagiline developed by Pharma Two B. Pharma Two B owns worldwide granted patents for both pharmaceutical composition and method of treatment with P2B001, which are expected to remain in force until January 2033. About Pharma Two B Pharma Two B is a private, venture-backed, late-stage pharmaceutical company established in 2008 in Rehovot, Israel. Our mission is to improve patients’ quality of life by developing innovative, value-added combination drugs for neurological disorders, with a clear unmet need, that are based on previously approved oral drugs and that offer meaningful clinical benefits, as well as improved safety and enhanced convenience through easier administration. The company is led by a highly experienced team in Parkinson Disease, supported by top tier scientific and clinical key opinion leaders, and backed by a dedicated group of investors. For more information, please visit: www.pharma2b.com. The content above comes from the network. if any infringement, please contact us to modify.

Accessible Care for Seniors Signing Up for Medicare Benefits CHICAGO, Nov. 8, 2022 /PRNewswire/ -- On October 15, open enrollment for Medicare began. Millions of seniors in Illinois will once again face the challenge of finding the right Medicare coverage, including the need to decide between Original Medicare or Medicare Advantage plans. While the primary focus will be on medical and prescription coverage, it is important not to ignore the potential impact of dental coverage. Continue Reading University Dental Professionals Most Medicare participants fail to understand Medicare does not include routine, preventive dental procedures that are critical to longevity and overall health. Currently, Medicare benefits only apply to surgical dental procedures carried out in hospitals. As a result, seniors must either pay for dental services completely out-of-pocket or try to find a Medicare supplement that provides high-quality, affordable and accessible dental care. Unfortunately, this is extremely difficult. Most Medicare dental supplements are low-cost and poorly designed. In addition, these plans have very limited networks of inexperienced dentists. "We understand the challenges seniors in this situation face, which is one reason why we offer the UDP Prevention Plan," commented Dr. Lou Graham at University Dental Professionals. He continued, "We make the search for experienced and knowledgeable dentists easy and provide the care seniors need at a rate they can afford. Our Plan allows these patients to enjoy friendly, personalized care at a consistent, annual fee." Furthermore, the negative impact of poor dental care on the overall health of seniors can be significant. A range of statistics tell the story: Only 29% of seniors have dental coverage. 1 in 5 adults aged 65 or older have no natural teeth remaining, and complete tooth loss becomes twice as prevalent by age 75. People who still have 20 or more teeth at age 70 are significantly more likely to have a longer lifespan than those with fewer teeth. 70% of adults over the age of 65 have advanced periodontitis. This is the leading cause of adult tooth loss. In Texas, nearly 4 million senior citizens struggle with periodontal disease – a disease that has been strongly linked to heart disease, Alzheimer's, diabetes, and other serious conditions. While dental membership plans have existed for more than 20 years, most patients are unaware of this option. At the same time, ease of use and enrollment are two of the most significant benefits. Other facts to know about the UDP Prevention Plan include: All, routine preventive care is included at a fixed cost per month. Benefits are available immediately without any waiting period. There are no annual limits, deductibles or co-pays. As seniors consider the benefits of the UDP Prevention Plan, it is important to keep a couple of dates in mind. Open enrollment for Medicare started on October 15, 2022, and ends December 7, 2022. This is the time to drop an existing dental supplement that is not working and to enroll in a better form of coverage. Families interested in learning more should feel free to contact University Dental Professionals via their website or by calling 773-684-5702. Contact Information: Website: Dr. Lou Graham 5549 S Cornell Ave Chicago, IL 60637 Candy Chaney, Client Relations TNT Dental 2100 North Collins Boulevard Richardson, TX 75080 Primary Media Contact: Candy Chaney 877-868-4932 [email protected] SOURCE University Dental Professionals